MasterCard Inc vs Oruka Therapeutics Inc. Common Stock — how do they compare? MasterCard Inc trades at $603.82 (market cap $529.81B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: MasterCard Inc is far larger — about 102.3× Oruka Therapeutics Inc. Common Stock's market cap, and MasterCard Inc pays a 0.58% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 135 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| MA | ORKA | |
|---|---|---|
Market Cap | $529.81B | $5.18B |
Volume | 3,710,695 | 490,798 |
Sector | Financials | Health |
52-Week High | $604.80 | $113.08 |
52-Week Low | $471.55 | $26.19 |
Typical Hold Time | 135 Days | 0 Days |
Enterprise Value | $542.84B | $4.31B |
Dividend Yield | 0.58% | — |
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $603.24, up 1.37% on the day, with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with consistent revenue growth from $22.2B in 2022 to $32.8B in 2025, net income margins above 45%, and three consecutive quarterly earnings beats. Institutional buying activity remains strong, with multiple funds increasing positions in Q4 2025.
Outlook remains positive with 80% analyst buy ratings and $668.67 consensus price target, representing 11% upside. Key risks include payment industry disruption from stablecoins and AI-driven competitors, though Mastercard's aggressive innovation strategy and expanding digital inclusion initiatives provide growth catalysts. The stock trades near resistance at $603 with support at $591.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →